Bio-Matrix' Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing Technology for Use in Tre...
February 26 2013 - 10:12AM
Marketwired
Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN) announced today
that its wholly owned subsidiary Regen BioPharma Inc. has entered
into a Letter of Intent ("LOI") to purchase patented intellectual
property covering a novel means of treating breast cancer by
augmenting the immune system using a "gene silencing" approach.
The technology has been published in peer-reviewed journals by
Professor Min, which documents its capacity of reducing tumors in
melanoma (Zheng et al. J Immunol. 2006 Oct 15;177(8):5639-46) and
breast cancer models (Zheng et al. Int J Cancer. 2013 Feb
15;132(4):967-77).
This gene silencing therapy was developed through over 1.5
million dollars of grant funding at the University of Western
Ontario, Canada. This approach offers the possibility of destroying
tumors in a non-toxic manner through leveraging the body's own
immune system to recognize the cancer as "foreign" and subsequently
eradicating it.
"For more than a decade our laboratory's focus has been to
identify how to use gene silencing in the context of immunology. We
are enthusiastic to have partnered with Bio-Matrix' Regen BioPharm.
We believe this novel approach in treating breast cancer will
greatly enhance outcomes for patients," said Professor Min. "While
Dendreon's Provenge cancer vaccine has provided an industry
precedent for immunotherapy as a practical alternative in oncology,
we believe that our approach is capable at competing both at the
cost, and efficacy level."
Provenge is a vaccine for prostate cancer that costs $93,000 per
treatment cycle(1) and had sales of $240 million in the last three
quarters of 2012, despite only increasing survival by 4.1
months(2). Dendreon's Provenge requires extraction of dendritic
cells, a "master cell" of the immune system, and manipulation
outside of the body. The technology developed by Professor Min
involves "training" of the same dendritic cells inside of the body
by administration of specific nanoparticles. Proof of concept of
these nanoparticles were published by Professor Min in
collaboration with University of California San Diego in the
prestigious scientific journal Blood (Zheng et al. Blood. 2009 Mar
19;113(12):2646-54).
"We are eager to continue working with Professor Min and his
team at taking his technology into cancer patients," said David
Koos, Chairman & CEO of Bio-Matrix Scientific Group Inc. "The
stellar academic record of Dr. Min and his continual involvement
should not only help accelerate our therapeutics development
process, but should also position us for numerous grant and
philanthropic funding to support the ongoing translational
development."
The transactions contemplated by the LOI are subject to the
execution of one or more definitive agreements on terms and
conditions mutually acceptable to the parties.
About Bio-Matrix Scientific Group Inc. and
Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), through
its wholly owned subsidiary Regen BioPharma, Inc., is a
biotechnology company focused on identifying undervalued
regenerative medicine and other niche patents, rapidly advancing
these technologies through pre-clinical and Phase I/ II clinical
trials and ultimately partnering or licensing these technologies to
large pharma companies for Phase III clinical trials and
commercialization. To follow our development, visit us at
www.regenbiopharma.com.
Disclaimer
This news release may contain forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks
(1)
http://finance.yahoo.com/news/dendreon-jumps-stronger-3q-provenge-154412408.html
(2)
http://seekingalpha.com/article/900031-dendreon-s-provenge-more-evidence-of-a-greater-life-extension-survival-benefit
Contact: Bio-Matrix Scientific Group, Inc. David R. Koos,
PhD Chairman & Chief Executive Officer 619-702-1404 Email
Contact